www.fdanews.com/articles/197847-contextvision-earns-ce-mark-for-prostate-screening-software
![CE mark](https://www.fdanews.com/ext/resources/images/ce-mark.gif?t=1627682539&width=430)
ContextVision Earns CE Mark for Prostate Screening Software
June 30, 2020
ContextVision has earned a CE mark for its artificial intelligence (AI)-based software for prostate cancer screening, INIFY Prostate Screening.
The INIFY Prostate Screening platform uses AI to predict and rank suspected cancerous areas in prostate biopsies. It automatically ranks slides from worst to best, allowing pathologists to target areas of concern.
The software can be used either as a standalone system or alongside other picture-archiving and communication systems.